TROP-2 overexpression in papillary renal cell carcinoma supports its potential as a therapeutic target for antibody-drug-conjugate therapy.

World J Urol · 2025 · PMC12401752 · PMID 40888912

Europe PMC DOI

hedged sentence

0.0810

closest p · 1.6× alpha

0.0810

boldest claim

The sentences

did not reach statistical significancep = 0.081so close (0.05 < p ≤ 0.1)

Although the difference in median overall survival (OS) between the two groups did not reach statistical significance (28.8 vs. 22.5 months, p = 0.081), IO-based regimens yielded significantly improved 1-year and 2-year OS rates ( p = 0.038 and p = 0.023, respectively) [ 3 ].

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.